Home
CTMX
CTMX News

Latest CytomX Therapeutics Inc. (CTMX) News on January 19, 2025

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

Zacks

6 days ago

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

11 days ago

CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy

Zacks

11 days ago

All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy

MT Newswires

12 days ago

Wedbush Adjusts CytomX Therapeutics' PT to $5 From $8, Keeps Outperform Rating

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

GlobeNewswire

12 days ago

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Zacks

13 days ago

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

Zacks

15 days ago

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Zacks

16 days ago

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Zacks

16 days ago

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Neumora Stock Hits Record Low on Depression Drug Study Failure

Zacks

16 days ago

Neumora Stock Hits Record Low on Depression Drug Study Failure

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

Zacks

16 days ago

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Zacks

17 days ago

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks

a month ago

CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Zacks

a month ago

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Grifols Stock Declines After Brookfield Drops Buyout Offer

Zacks

2 months ago

Grifols Stock Declines After Brookfield Drops Buyout Offer

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

GlobeNewswire

2 months ago

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

Zacks

2 months ago

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Zacks

2 months ago

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Zacks

2 months ago

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround

Zacks

2 months ago

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

Zacks

2 months ago

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

2 months ago

CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Thomson Reuters StreetEvents

2 months ago

Q3 2024 CytomX Therapeutics Inc Earnings Call

CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

GuruFocus.com

2 months ago

CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates

Zacks

2 months ago

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates

Associated Press Finance

2 months ago

CytomX Therapeutics: Q3 Earnings Snapshot

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

2 months ago

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result

GuruFocus.com

2 months ago

Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

GlobeNewswire

3 months ago

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

GlobeNewswire

4 months ago

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

CytomX Therapeutics to Present at Upcoming September Investor Conferences

GlobeNewswire

4 months ago

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CytomX Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

5 months ago

CytomX Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Associated Press Finance

5 months ago

CytomX Therapeutics: Q2 Earnings Snapshot

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

5 months ago

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

GlobeNewswire

6 months ago

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

CytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now?

Insider Monkey

6 months ago

CytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 47% of the company

Simply Wall St.

6 months ago

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 47% of the company

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

GlobeNewswire

7 months ago

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

GlobeNewswire

7 months ago

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago

Simply Wall St.

7 months ago

Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

8 months ago

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire

8 months ago

CytomX Therapeutics Announces New Employment Inducement Grants

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript

Insider Monkey

8 months ago

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript

MT Newswires

8 months ago

BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating

Thomson Reuters StreetEvents

8 months ago

Q1 2024 CytomX Therapeutics Inc Earnings Call

MT Newswires

8 months ago

Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3

GuruFocus.com

8 months ago

CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...

Associated Press Finance

8 months ago

CytomX Therapeutics: Q1 Earnings Snapshot

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

GlobeNewswire

8 months ago

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

8 months ago

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

GlobeNewswire

8 months ago

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

MT Newswires

8 months ago

Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8

CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?

Zacks

9 months ago

CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

GlobeNewswire

9 months ago

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

Here's Why We're Not Too Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Simply Wall St.

9 months ago

Here's Why We're Not Too Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

GlobeNewswire

9 months ago

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

GlobeNewswire

10 months ago

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

GlobeNewswire

10 months ago

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

GlobeNewswire

10 months ago

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

10 months ago

CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript

Insider Monkey

10 months ago

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

10 months ago

Q4 2023 CytomX Therapeutics Inc Earnings Call

CytomX Therapeutics Inc (CTMX) Reports 2023 Financial Results and Provides Pipeline Update

GuruFocus.com

10 months ago

CytomX Therapeutics Inc (CTMX) Reports 2023 Financial Results and Provides Pipeline Update

CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates

Zacks

10 months ago

CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

GlobeNewswire

10 months ago

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

GlobeNewswire

a year ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect

Zacks

a year ago

CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect

CytomX Therapeutics to Present at Upcoming March Investor Conferences

GlobeNewswire

a year ago

CytomX Therapeutics to Present at Upcoming March Investor Conferences

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) largest shareholders are retail investors with 50% ownership, institutions own 29%

Simply Wall St.

a year ago

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) largest shareholders are retail investors with 50% ownership, institutions own 29%

LiveOne (Nasdaq: LVO) Launches "Splitmind Radio" Exclusively on Slacker Radio

NewMediaWire

a year ago

LiveOne (Nasdaq: LVO) Launches "Splitmind Radio" Exclusively on Slacker Radio

Marine Products Corporation (NYSE:MPX) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Marine Products Corporation (NYSE:MPX) Q4 2023 Earnings Call Transcript

Cango Announces Strategic Partnership with Caocao Mobility for Next-Generation Smart Mobility Ecosystem

PR Newswire

a year ago

Cango Announces Strategic Partnership with Caocao Mobility for Next-Generation Smart Mobility Ecosystem

BNY Mellon High Yield Strategies Fund Declares Dividend

Business Wire

a year ago

BNY Mellon High Yield Strategies Fund Declares Dividend

Southern States Bancshares Inc (SSBK) Reports Mixed Q4 Earnings Amid Interest Rate Challenges

GuruFocus.com

a year ago

Southern States Bancshares Inc (SSBK) Reports Mixed Q4 Earnings Amid Interest Rate Challenges

Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why

Zacks

a year ago

Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why

Zacks

a year ago

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

GlobeNewswire

a year ago

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

Gran Tierra Energy Inc. Announces Strong Reserves Replacement and Meaningful Reserves Growth in 2023

GlobeNewswire

a year ago

Gran Tierra Energy Inc. Announces Strong Reserves Replacement and Meaningful Reserves Growth in 2023

Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal

Zacks

a year ago

Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

Zacks

a year ago

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback

Zacks

a year ago

Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback

Byrna Technologies Partners with Leading Multi-Media Personality Glenn Beck

PR Newswire

a year ago

Byrna Technologies Partners with Leading Multi-Media Personality Glenn Beck

AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal

Zacks

a year ago

AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal

Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates

Zacks

a year ago

Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates

Why It Might Not Make Sense To Buy William Penn Bancorporation (NASDAQ:WMPN) For Its Upcoming Dividend

Simply Wall St.

a year ago

Why It Might Not Make Sense To Buy William Penn Bancorporation (NASDAQ:WMPN) For Its Upcoming Dividend

Genetron Health to Hold Extraordinary General Meeting of Shareholders

GlobeNewswire

a year ago

Genetron Health to Hold Extraordinary General Meeting of Shareholders

RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS

Business Wire

a year ago

RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS

QuickLogic (QUIK) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

a year ago

QuickLogic (QUIK) Is a Great Choice for 'Trend' Investors, Here's Why

Innodata to Participate in Needham's 26th Annual Growth Conference

ACCESSWIRE

a year ago

Innodata to Participate in Needham's 26th Annual Growth Conference

At US$3.06, Is MYT Netherlands Parent B.V. (NYSE:MYTE) Worth Looking At Closely?

Simply Wall St.

a year ago

At US$3.06, Is MYT Netherlands Parent B.V. (NYSE:MYTE) Worth Looking At Closely?

Leftovers: Dunkin’ muscles into protein powder | Danone whips up International Delight cold foam creamer

Food Dive

a year ago

Leftovers: Dunkin’ muscles into protein powder | Danone whips up International Delight cold foam creamer

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire

a year ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

FARO Successfully Completes SOC 2 Type II Audit

PR Newswire

a year ago

FARO Successfully Completes SOC 2 Type II Audit

TeraWulf Reports Fully Funded 7.9 EH/s and Future Expansion Plans

GlobeNewswire

a year ago

TeraWulf Reports Fully Funded 7.9 EH/s and Future Expansion Plans

Does Marine Products (NYSE:MPX) Deserve A Spot On Your Watchlist?

Simply Wall St.

a year ago

Does Marine Products (NYSE:MPX) Deserve A Spot On Your Watchlist?

Should You Invest in Bluebird Bio Right Now?

Motley Fool

a year ago

Should You Invest in Bluebird Bio Right Now?

Business Wire

a year ago

Stratasys Adopts Limited Duration Shareholder Rights Plan with Enhanced Shareholder Protections

Zacks Small Cap Research

a year ago

XFOR: Update on Phase 2 CN Trial at ASH 2023

Those who invested in Escalade (NASDAQ:ESCA) a year ago are up 110%

Simply Wall St.

a year ago

Those who invested in Escalade (NASDAQ:ESCA) a year ago are up 110%

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

GlobeNewswire

a year ago

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Share on Social Networks: